Your annual physical isn't built for early detection.

By Dr. Georgine Nanos, MD, MPH | Board-Certified Family Physician, Kind Health Group — Encinitas, CA

Carol was 54 and had no symptoms, no family history of cancer, no reason to be alarmed. She came in for her annual visit and we talked about a relatively new blood test called Galleri — a multi-cancer early detection test that screens for signals from more than 50 cancer types in a single blood draw. She agreed to take it. Three weeks later, the results came back with a positive signal for pancreatic cancer. A follow-up scan confirmed it: Stage 1. Pancreatic cancer is almost never found at Stage 1. Carol is alive today because of a blood test that most physicians still haven't heard of.

The Annual Physical Was Never Designed to Catch Early Cancer

The standard annual physical is built to confirm you aren't acutely dying. It checks blood pressure, weight, basic blood chemistry, and whatever age-appropriate screening guidelines your insurance covers. For most adults over 40, that means a mammogram, a colonoscopy every ten years, and a Pap smear. It does not mean proactive surveillance for the cancers most likely to kill you before symptoms appear.

The problem with relying on symptoms to catch cancer is that symptoms are a late-stage phenomenon. By the time pancreatic cancer causes pain or jaundice, it's almost always Stage 4. By the time ovarian cancer causes noticeable symptoms, it has typically spread beyond the ovary. By the time most lung cancers are symptomatic in non-smokers — who aren't routinely screened — they're advanced. The annual physical isn't designed to find these cancers early. It's designed to find things that are already visible and obvious.

This is a structural problem in how medicine is practiced, not a failure of individual physicians. The standard-of-care screening guidelines are set by population-level cost-benefit analysis, not by what would be optimal for any specific individual. When you hear "screening isn't recommended until age 50" or "this test isn't standard of care," what that means is the general population doesn't benefit enough in aggregate to justify routine coverage. It says nothing about whether the test would benefit you specifically.

The shift from reactive to proactive medicine is one of the most important conversations happening in health right now. It starts with the recognition that "no symptoms" does not mean "no disease" — and that the technology to detect disease before symptoms appear now actually exists.

What the Science Says About Early Detection

The survival statistics for cancer are starkly, clearly about stage at diagnosis. For pancreatic cancer, the 5-year survival rate at Stage 1 is approximately 44%. At Stage 4, it's 3%. For ovarian cancer: Stage 1 survival is around 93%. Stage 4 is 29%. For lung cancer: Stage 1A is 85% survival. Stage 4 is 10%. The stage of diagnosis is one of the single most powerful determinants of whether you survive. Finding cancer earlier isn't a medical nicety. It's often the difference between life and death.

The Galleri test, developed by Grail and now commercially available, detects cell-free DNA fragments shed by tumors into the bloodstream. A landmark 2021 study published in Annals of Oncology validated the test across a population of 6,600 individuals, finding that it correctly identified cancer with a false positive rate of less than 1%. Importantly, when it detects a cancer signal, it also predicts the tissue of origin with over 90% accuracy — meaning it can tell you not just that something may be wrong, but where in your body to look.

A subsequent PATHFINDER study (2023, published in The Lancet) followed 6,621 adults who received the Galleri test as part of routine care. Cancer was detected in 1.4% of participants, and in the majority of cases the test identified cancers that would not have been found through standard screening — often at earlier stages than would have been typical. The clinical implication is significant: this test finds cancers that current protocols miss.

Prenuvo, a whole-body MRI designed specifically for early disease detection, provides a complementary but different type of surveillance. A 2023 paper in Radiology described Prenuvo's ability to detect early-stage organ abnormalities, vascular disease, and structural changes that precede symptomatic disease — including early kidney tumors, liver lesions, and arterial stenosis. Unlike CT or PET scans, it uses no radiation and no contrast injection, making it suitable for annual surveillance.

Advanced cardiac and metabolic biomarkers — including ApoB, Lp(a), coronary artery calcium scoring, hs-CRP, and advanced lipid panels — provide early warning for cardiovascular risk that a standard cholesterol panel completely misses. Lp(a), a genetic cardiovascular risk factor present in roughly 20% of the population, is not measured in standard lipid panels. Yet it's one of the strongest independent predictors of early heart attack.

Three Technologies That Are Changing the Game

The Galleri multi-cancer early detection test is a single blood draw that screens for signals from more than 50 cancer types. It looks for cell-free DNA shed by cancer cells into the bloodstream and, when a signal is detected, identifies the tissue of origin. It's not a replacement for existing cancer screening protocols — it's additive. It finds cancers that mammograms, colonoscopies, and Pap smears don't. Carol's pancreatic cancer is the most dramatic illustration of this, but patients have also found early lung, esophageal, and lymphoid cancers through Galleri that would have gone undetected for years.

The Prenuvo whole-body MRI takes approximately 60 minutes and produces a detailed scan of over 500 anatomical features, looking for early-stage abnormalities in the brain, spine, chest, abdomen, and pelvis. It uses no radiation and no contrast dye. The scan is reviewed by board-certified radiologists and reported to your physician with a full findings summary. For patients who want a comprehensive structural picture of their body's current health status, it provides a level of surveillance that simply doesn't exist in standard medicine.

Advanced biomarker panels go beyond standard lipid and metabolic tests to include ApoB (a more accurate predictor of cardiovascular risk than LDL), Lp(a) (a genetic cardiovascular risk factor), hs-CRP (a marker of systemic inflammation), homocysteine, and detailed metabolic markers including fasting insulin and advanced glucose metabolism measures. These panels identify cardiovascular and metabolic risk years before a standard panel would flag anything abnormal — giving us a real window to intervene.

What Proactive Health Screening Looks Like at Kind Health Group

At Kind Health Group in Encinitas, proactive health surveillance is a core part of how we practice medicine. The annual physical at KHG is not a box-checking exercise. It's a comprehensive evaluation designed to identify what's coming — not just what's already here.

For appropriate patients, we offer Galleri testing as part of an annual cancer screening protocol. We discuss the test, the evidence behind it, the implications of a positive result, and how to think about it in the context of your individual risk profile. If a signal is detected, we have a coordinated protocol for follow-up imaging and specialist referral.

We also offer referrals and coordination for Prenuvo whole-body MRI for patients who want structural surveillance beyond what standard imaging provides. And we use advanced biomarker panels as a standard part of cardiovascular and metabolic risk assessment — not an optional add-on.

This kind of proactive medicine requires time. It requires a physician who knows you, your history, and your risk factors well enough to make personalized recommendations. That's not possible in a seven-minute appointment. It's what we built Kind Health Group to do.

What You Can Do Right Now

Ask your physician about the Galleri test. It's commercially available, costs approximately $900, and is not covered by most insurance — but for what it screens and the cancers it can catch, it's one of the highest-value health investments available. If your physician hasn't heard of it, that's a conversation worth having.

Request Lp(a) testing. This is a simple blood test that measures a genetic cardiovascular risk factor present in 1 in 5 people. It is not included in standard lipid panels. Elevated Lp(a) significantly increases heart attack and stroke risk and requires specific management strategies. Ask for it by name.

Consider a Prenuvo scan if you're between 40 and 70 with no symptoms but a desire for comprehensive structural surveillance. Check prenuvo.com for current locations and pricing.

If you're in San Diego, schedule a proactive health consultation at Kind Health Group in Encinitas. We'll review your current screening status, discuss advanced testing options, and build a personalized early detection protocol.

Frequently Asked Questions

What is the Galleri cancer test?

The Galleri test is a multi-cancer early detection blood test developed by Grail that screens for cell-free DNA signals from more than 50 cancer types in a single blood draw. When a signal is detected, it also identifies the tissue of origin with over 90% accuracy. It is intended as an additive screening tool alongside existing protocols, not a replacement for mammograms or colonoscopies.